IGHE and Alzheimer disease: Our study’s limitations include not being prospective, not having a control group, not using a standardized symptom score to clinically evaluate SCIT efficacy (for AR and AD) and not being able to measure valuable markers such as antigen-specific IgE and IgG4, regulatory cytokines, and cells that can be used to evaluate tolerance after SCIT.